BioCentury
ARTICLE | Product R&D

Eyeing fewer needles

How Eyevensys aims to replace intravitreal injections with gene therapies

December 3, 2015 8:00 AM UTC

Eyevensys S.A.S. is creating a non-viral gene therapy platform for ophthalmic diseases that can deliver steady, low levels of therapeutic protein to the eye for up to a year with a single treatment. Having raised a €7.5 million ($7.9 million) series A round in October, the company is gearing up to file an IND in January on its first compound, EYS606, a TNFα-quenching gene therapy for non-infectious uveitis.

However, while the biotech believes its technology will offer better safety and efficacy than injectables, it faces steep competition from a burst of new technologies also aiming for better PK profiles and less invasive delivery than the ophthalmic therapies that have entered the market in the last 10 years. ...